Unique ID issued by UMIN | UMIN000003675 |
---|---|
Receipt number | R000004457 |
Scientific Title | Impact of functional imaging on the evaluation of treatment effect after neoadjuvant chemoradiation therapy for non-small cell lung cancer |
Date of disclosure of the study information | 2010/05/31 |
Last modified on | 2017/02/15 23:16:29 |
Impact of functional imaging on the evaluation of treatment effect after neoadjuvant chemoradiation therapy for non-small cell lung cancer
Impact of functional imaging on the evaluation of treatment effect after neoadjuvant chemoradiation therapy for non-small cell lung cancer
Impact of functional imaging on the evaluation of treatment effect after neoadjuvant chemoradiation therapy for non-small cell lung cancer
Impact of functional imaging on the evaluation of treatment effect after neoadjuvant chemoradiation therapy for non-small cell lung cancer
Japan |
Non-Small Cell Lung Cancer
Pneumology | Chest surgery | Radiology |
Malignancy
NO
To detect an useful index about the treatment effect prediction of neoadjuvant chemoradiation therapy for non-small cell lung cancer by evaluating of changes of functional imaging before and after neoadjuvant chemoradiation therapy and the pathological information obtained after operation.
Others
Utility of functional imaging about treatment effect prediction
Accuracy of treatment effect prediction by functional imaging
Pathological response of preoperative therapy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Diagnosis
Device,equipment |
Undergo PET/CT and plain MRI (including diffusion-weighted image) before and after neoadjuvant chemoradiation therapy.
Not applicable |
Not applicable |
Male and Female
1.Histologically confirmed Non-small cell lung cancer.
2.Adequate bone marrow function
WBC more than 4000/ul, Platelet count more than 100,000/ul.
3.Adequate liver function.
(T.Bil less than 1.5mg/dl)
4.Adequate renal level.
(serum creatinin less than 1.5mg/dl, Creatinine clearlance more than 60mg/dl)
5.Adequate pulmonary function
(PaO2 more than 70Torr)
6. No other severe complications. Agreement for the protocol by physicians, surgeons and radiologists is essential.
7.Written informed consent to participate in the trial is necessary
1.Malignant pleuritis or malignant pericarditis.
2.Pleural dissemination.
3.Patients with severe complications.
a.Pulmonary fibrosis.
b.Severe heart disease.(Uncontrollable angina or myocardial infarction within the past 3 months)
c.Uncontrollable Diabetes Mellitus.
d.Severe infectious disease
e.Other unsuitable patient judged by a physician.
4.Women during pregnancy or lactating.
20
1st name | |
Middle name | |
Last name | Yoichi Otomi |
University of Tokushima
Department of radiology
2-50-1, Kuramoto-cho, Tokushima
088-633-9283
otomi.yoichi@tokushima-u.ac.jp
1st name | |
Middle name | |
Last name | Yoichi Otomi |
University of Tokushima
Department of radiology
2-50-1, Kuramoto-cho, Tokushima
088-633-9283
otomi.yoichi@tokushima-u.ac.jp
University of Tokushima
None
Self funding
NO
2010 | Year | 05 | Month | 31 | Day |
Unpublished
Terminated
2010 | Year | 07 | Month | 01 | Day |
2010 | Year | 07 | Month | 01 | Day |
2010 | Year | 05 | Month | 30 | Day |
2017 | Year | 02 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004457